Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599462 | 0.88 | CCNC (0.50) | EPHX2NCF1 | |
| SCHEMBL4966832 | 0.87 | PDGFRB (0.71) | KITPDGFRAPDGFRBFLT3KDR | |
| SCHEMBL4965795 | 0.86 | PDGFRB (0.66) | KITPDGFRAPDGFRBFLT3KDR | |
| SCHEMBL14599459 | 0.86 | PDGFRB (0.54) | KITPDGFRAPDGFRBFLT3NCF1 | |
| SCHEMBL4967296 | 0.81 | PDGFRB (0.64) | KITPDGFRAPDGFRBFLT3KDR | |
| SCHEMBL5518895 | 0.80 | EPHX2 (0.54) | PDGFRBEPHX2TP53EPHX1NFKB1 | |
| SCHEMBL4969487 | 0.79 | ENPP1 (0.53) | KITPDGFRAPDGFRBFLT3KDR | |
| SCHEMBL14599468 | 0.79 | EPHX2 (0.48) | KITPDGFRAKDREPHX2 | |
| SCHEMBL14599466 | 0.78 | AURKA (0.61) | FLT3KDREPHX2 | |
| SCHEMBL22455401 | 0.78 | NCF1 (0.56) | KITPDGFRAPDGFRBNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | KIT 104/4885PDGFRA 74/4885PDGFRB 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.